Literature DB >> 24477413

Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.

Megan M Weivoda1, Merry Jo Oursler.   

Abstract

The SOST gene, which encodes the protein sclerostin, was identified through genetic linkage analysis of sclerosteosis and van Buchem's disease patients. Sclerostin is a secreted glycoprotein that binds to the low-density lipoprotein receptor-related proteins 4, 5, and 6 to inhibit Wnt signaling. Since the initial discovery of sclerostin, much understanding has been gained into the role of this protein in the regulation of skeletal biology. In this article, we discuss the latest findings in the regulation of SOST expression, sclerostin mechanisms of action, and the potential utility of targeting sclerostin in conditions of low bone mass.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477413      PMCID: PMC4009626          DOI: 10.1007/s11914-014-0188-1

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  69 in total

1.  Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women.

Authors:  Juliet McColm; Leijun Hu; Theresa Womack; Cheng Cai Tang; Alan Y Chiang
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

2.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

Review 3.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

4.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

5.  SOST is a target gene for PTH in bone.

Authors:  Hansjoerg Keller; Michaela Kneissel
Journal:  Bone       Date:  2005-08       Impact factor: 4.398

6.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

7.  Smad proteins function as co-modulators for MEF2 transcriptional regulatory proteins.

Authors:  Z A Quinn; C C Yang; J L Wrana; J C McDermott
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

8.  Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.

Authors:  Masakazu Kogawa; Asiri R Wijenayaka; Renee T Ormsby; Gethin P Thomas; Paul H Anderson; Lynda F Bonewald; David M Findlay; Gerald J Atkins
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

9.  Sclerostin: Another vascular calcification inhibitor?

Authors:  Kathleen J Claes; Liesbeth Viaene; Sam Heye; Björn Meijers; Patrick d'Haese; Pieter Evenepoel
Journal:  J Clin Endocrinol Metab       Date:  2013-06-20       Impact factor: 5.958

10.  Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study.

Authors:  Vincent M Brandenburg; Rafael Kramann; Ralf Koos; Thilo Krüger; Leon Schurgers; Georg Mühlenbruch; Sinah Hübner; Ulrich Gladziwa; Christiane Drechsler; Markus Ketteler
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

View more
  12 in total

Review 1.  The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives.

Authors:  Catarina Carvalho; Catarina Moniz Alves; João Miguel Frazão
Journal:  J Nephrol       Date:  2016-07-29       Impact factor: 3.902

2.  Intermittent administration of PTH induces the expression of osteocalcin and BMP-2 on choroid plexus cells associated with suppression of sclerostin, TGF-β1, and Na+K+ATPase.

Authors:  Allan Fernando Giovanini; Isabella Göhringer; Rosangela Tavella; Manuelly Cristiny Linzmeyer; Thaynara Fernanda Priesnitz; Luana Mordask Bonetto; Rafaela Guimarães Resende; Rafaela Scariot; João Cesar Zielak
Journal:  Endocrine       Date:  2017-12-12       Impact factor: 3.633

Review 3.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 4.  Sclerostin Inhibition in the Management of Osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Calcif Tissue Int       Date:  2016-03-26       Impact factor: 4.333

5.  Short-term intermittent administration of parathyroid hormone facilitates osteogenesis by different mechanisms in cancellous and cortical bone.

Authors:  Kenji Ogura; Tadahiro Iimura; Yuji Makino; Ayano Sugie-Oya; Aya Takakura; Ryoko Takao-Kawabata; Toshinori Ishizuya; Keiji Moriyama; Akira Yamaguchi
Journal:  Bone Rep       Date:  2016-01-16

6.  Circulating sclerostin is not suppressed following a single bout of exercise in young men.

Authors:  Katelyn I Guerriere; Julie M Hughes; Erin Gaffney-Stomberg; Jeffery S Staab; Ronald W Matheny
Journal:  Physiol Rep       Date:  2018-05

7.  Response of Sclerostin and Bone Turnover Markers to High Intensity Interval Exercise in Young Women: Does Impact Matter?

Authors:  R Kouvelioti; N Kurgan; B Falk; W E Ward; A R Josse; P Klentrou
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

Review 8.  Bone function, dysfunction and its role in diseases including critical illness.

Authors:  Nan Su; Jing Yang; Yangli Xie; Xiaolan Du; Hangang Chen; Hong Zhou; Lin Chen
Journal:  Int J Biol Sci       Date:  2019-01-29       Impact factor: 6.580

Review 9.  Role of osteocytes in multiple myeloma bone disease.

Authors:  Jesus Delgado-Calle; Teresita Bellido; G David Roodman
Journal:  Curr Opin Support Palliat Care       Date:  2014-12       Impact factor: 2.302

10.  The Bromodomain Inhibitor N-Methyl pyrrolidone Prevents Osteoporosis and BMP-Triggered Sclerostin Expression in Osteocytes.

Authors:  Barbara Siegenthaler; Chafik Ghayor; Bebeka Gjoksi-Cosandey; Nisarat Ruangsawasdi; Franz E Weber
Journal:  Int J Mol Sci       Date:  2018-10-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.